{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:27:02Z","timestamp":1770895622514,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["Max-Eder Program"],"award-info":[{"award-number":["Max-Eder Program"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The addition of midostaurin to standard chemotherapy has improved survival in patients with <jats:italic>FLT3<\/jats:italic>-mutated AML. However, the impact of midostaurin and other FLT3 inhibitors (FLT3i) on cardiovascular adverse events (CAEs) has not been studied in patients who underwent allogeneic hematopoietic stem cell transplantation in a real-world setting. We reviewed 132 patients with AML who were treated with intensive induction therapy and consecutive allogeneic stem cell transplantation at our institution (42 <jats:italic>FLT3<\/jats:italic>-mutated AML and 90 with <jats:italic>FLT3<\/jats:italic> wildtype). We identified treatment with midostaurin and\/or FLT3i as an independent risk factor for CAEs not resulting in higher non-relapse mortality (NRM) or impaired overall survival (OS). Hence, close monitoring for CAEs is warranted for these patients.<\/jats:p>","DOI":"10.1007\/s00277-023-05396-y","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T08:01:56Z","timestamp":1691481716000},"page":"2903-2908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4701-842X","authenticated-orcid":false,"given":"Anjali","family":"Cremer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius C.","family":"Enssle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia","family":"Pfaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khouloud","family":"Kouidri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Brandts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Zeiher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Cremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"issue":"24","key":"5396_CR1","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1182\/blood-2010-04-261867","volume":"116","author":"T Kindler","year":"2010","unstructured":"Kindler T, Lipka DB, Fischer T (2010) FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116(24):5089\u20135102","journal-title":"Blood"},{"issue":"5","key":"5396_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD et al (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377(5):454\u2013464","journal-title":"N Engl J Med"},{"issue":"4","key":"5396_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447","journal-title":"Blood"},{"issue":"13","key":"5396_CR4","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","volume":"100","author":"S Frohling","year":"2002","unstructured":"Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100(13):4372\u20134380","journal-title":"Blood"},{"issue":"7","key":"5396_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","volume":"30","author":"S Brunet","year":"2012","unstructured":"Brunet S, Labopin M, Esteve J, Cornelissen J, Socie G, Iori AP et al (2012) Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 30(7):735\u2013741","journal-title":"J Clin Oncol"},{"issue":"4","key":"5396_CR6","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1182\/blood-2006-04-015826","volume":"110","author":"AJ Mead","year":"2007","unstructured":"Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE (2007) FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110(4):1262\u20131270","journal-title":"Blood"},{"issue":"2","key":"5396_CR7","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1182\/blood-2008-02-140392","volume":"112","author":"AJ Mead","year":"2008","unstructured":"Mead AJ, Gale RE, Hills RK, Gupta M, Young BD, Burnett AK et al (2008) Conflicting data on the prognostic significance of FLT3\/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. Blood 112(2):444\u20135 author reply 5","journal-title":"Blood"},{"issue":"5","key":"5396_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood.2019002697","volume":"135","author":"K Dohner","year":"2020","unstructured":"Dohner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA et al (2020) Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood 135(5):371\u2013380","journal-title":"Blood"},{"issue":"6","key":"5396_CR9","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","volume":"105","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Dalle IA et al (2020) Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the acute leukemia working party of the european society for blood and marrow transplantation. Haematologica 105(6):1507\u20131516","journal-title":"Haematologica"},{"issue":"26","key":"5396_CR10","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Rollig C et al (2020) Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol 38(26):2993\u20133002","journal-title":"J Clin Oncol"},{"issue":"18","key":"5396_CR11","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S et al (2019) Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 381(18):1728\u20131740","journal-title":"N Engl J Med"},{"issue":"7","key":"5396_CR12","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N et al (2019) Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 20(7):984\u2013997","journal-title":"Lancet Oncol"},{"issue":"8","key":"5396_CR13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","volume":"133","author":"RF Schlenk","year":"2019","unstructured":"Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H et al (2019) Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood 133(8):840\u2013851","journal-title":"Blood"},{"issue":"6","key":"5396_CR14","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1182\/blood-2018-01-821629","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL et al (2018) Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood 132(6):598\u2013607","journal-title":"Blood"},{"issue":"8","key":"5396_CR15","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912\u20132919","journal-title":"Blood"},{"issue":"2","key":"5396_CR16","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","volume":"3","author":"R Dulery","year":"2021","unstructured":"Dulery R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E et al (2021) Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation. JACC CardioOncol 3(2):250\u2013259","journal-title":"JACC CardioOncol"},{"key":"5396_CR17","doi-asserted-by":"crossref","unstructured":"Choudhary A, Manouchehri A, Moslehi J, Salem J (2020) Abstract 12978: identification of cardiovascular adverse effects associated with midostaurin - a WHO pharmacovigilance database analysis. Circulation 142:A12978","DOI":"10.1161\/circ.142.suppl_3.12978"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05396-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05396-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05396-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T10:05:58Z","timestamp":1694253958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05396-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["5396"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05396-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]},"assertion":[{"value":"12 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G.B. received research support from Novartis and honoraria and travel expenses from Jazz, Celgene, Novartis, and Gilead. The remaining authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}